Transcode Therapeutics Inc (RNAZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.08 Million) by net assets ($1.43 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Transcode Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Transcode Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Transcode Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Transcode Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transcode Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lanakam S.A
AT:LANAC
|
0.007x |
|
Lianhua Supermarket Holdings Co. Ltd
F:LSJ
|
0.734x |
|
Wah Fu Education Group Ltd
NASDAQ:WAFU
|
0.019x |
|
Advanced Biomed Inc. Common Stock
NASDAQ:ADVB
|
-0.002x |
|
EVE Health Group Limited
AU:EVE
|
-0.242x |
|
Swift Tv Ltd
AU:STV
|
-0.137x |
|
DTI Group Ltd
AU:DTI
|
-0.075x |
|
Platina Resources Limited
F:P4R
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Transcode Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Transcode Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Transcode Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.02 Million | $-13.34 Million | 6.606x | +159.97% |
| 2023-12-31 | $1.64 Million | $-18.07 Million | -11.016x | -126.48% |
| 2022-12-31 | $3.24 Million | $-15.76 Million | -4.864x | -1784.33% |
| 2021-12-31 | $20.40 Million | $-5.27 Million | -0.258x | -278.46% |
| 2020-12-31 | $-3.41 Million | $-492.97K | 0.145x | -68.78% |
| 2019-12-31 | $-1.10 Million | $-508.51K | 0.463x | -22.05% |
| 2018-12-31 | $-503.97K | $-299.57K | 0.594x | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more